# A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures

> **NCT01866111** · PHASE2 · COMPLETED · sponsor: **SK Life Science, Inc.** · enrollment: 437 (actual)

## Conditions studied

- Partial Epilepsy

## Interventions

- **DRUG:** YKP3089
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01866111
- **Lead sponsor:** SK Life Science, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-31
- **Primary completion:** 2021-04-05
- **Final completion:** 2021-10-31
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01866111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01866111, "A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01866111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*